STAT+: Pharmalittle: We’re reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more
Why it matters: The FDA's decision could reintroduce previously banned injectable peptides to the market via compounding pharmacies.
- The FDA is considering allowing compounding pharmacies to produce injectable peptides, reversing a prior ban due to safety concerns (Pharmalittle).
- Dr. Makary has completed one year at the FDA, focusing on his achievements in a speech to staff (STAT+).
- A government watchdog is urging the FDA to finalize guidance regarding conflicts of interest for advisory committees (STAT+).
The FDA is reportedly moving to reverse its ban on compounding pharmacies producing injectable peptides, despite previous safety concerns, a decision that comes as Dr. Makary marks his first year leading the agency. This shift occurs while a government watchdog simultaneously pressures the FDA to finalize guidance on advisory committee conflicts of interest, highlighting broader scrutiny on the agency's regulatory processes.
